抗生素
肠道菌群
艰难梭菌
医学
疾病
药品
利福昔明
免疫学
生物
微生物学
药理学
内科学
作者
Gianluca Ianiro,Herbert Tilg,Antonio Gasbarrini
出处
期刊:Gut
[BMJ]
日期:2016-08-16
卷期号:65 (11): 1906-1915
被引量:545
标识
DOI:10.1136/gutjnl-2016-312297
摘要
The recent increase in our knowledge of human gut microbiota has changed our view on antibiotics. Antibiotics are, indeed, no longer considered only beneficial, but also potentially harmful drugs, as their abuse appears to play a role in the pathogenesis of several disorders associated with microbiota impairment (eg, Clostridium difficile infection or metabolic disorders). Both drug-related factors (such as antibiotic class, timing of exposure or route of administration) and host-related factors appear to influence the alterations of human gut microbiota produced by antibiotics. Nevertheless, antibiotics are nowadays considered a reliable therapy for some non-communicable disorders, including IBS or hepatic encephalopathy. Moreover, some antibiotics can also act positively on gut microbiota, providing a so-called ‘eubiotic’ effect, by increasing abundance of beneficial bacteria. Therefore, antibiotics appear to change, for better or worse, the nature of several disorders, including IBS, IBD, metabolic disorders or liver disease. This reviews aims to address the potential of antibiotics in the development of major non-communicable disorders associated with the alteration of gut microbiota and on newly discovered therapeutic avenues of antibiotics beyond the cure of infectious diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI